VLA 0.00% $1.75 viralytics limited

Merck ditches Cavatak 4 years after buying Viralytics

  1. 373 Posts.
    lightbulb Created with Sketch. 349
    Well, well, well. I missed this happening last October. But I did predict during the buy-out that not only were we being ripped off, but Cavatak would never be used to help people. This is what big pharma does - swallows up any company showing promise so they can stop a potential "cure". There is no money to be made from curing people.

    https://www.fiercebiotech.com/biotech/merck-ditches-cavatak-more-four-years-after-buying-viralytics#:~:text=A%20spokesperson%20for%20Merck%20confirmed,treat%20a%20range%20of%20cancers
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.